This Article Full Text Full Text (PDF) All Versions of this Article: 200308-1159OCv1 169/10/1103    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chan, E. D. Articles by Iseman, M. D. Search for Related Content PubMed PubMed Citation Articles by Chan, E. D. Articles by Iseman, M. D.

Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant Tuberculosis

Department of Medicine, Program in Cell Biology and Division of Biostatistics, National Jewish Medical and Research Center; Division of Pulmonary Sciences and Critical Care Medicine and Division of Infectious Diseases, University of Colorado Health Sciences Center; Denver Veterans Administration Medical Center, Denver, Colorado; and Wilford Hall USAF Medical Center, San Antonio, Texas

Correspondence and requests for reprints should be addressed to Michael D. Iseman, M.D., J223, Molly Blank Building, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206. E-mail: isemanm{at}njc.org

Multidrug-resistant tuberculosis, a disease caused by Mycobacterium tuberculosis strains that are resistant at least to rifampin and isoniazid, entails extended treatment, expensive and toxic regimens, and higher rates of treatment failure and death. We retrospectively analyzed the outcomes in 205 patients treated at our center for multidrug-resistant tuberculosis, with strains resistant to a median of six drugs, and compared the results with those of our previous series. Logistic regression and survival analysis were used to evaluate short- and long-term outcomes, respectively. Initial favorable response, defined as at least three consecutive negative sputum cultures over a period of at least 3 months, was 85% compared with 65% in the prior cohort. The current cohort had greater long-term success rates, 75% versus 56%, and lower tuberculosis death rates, 12% versus 22%, than the earlier one. Surgical resection and fluoroquinolone therapy were associated with improved microbiological and clinical outcomes in the 205 patients studied after adjusting for other variables. The improvement was statistically significant for surgery and among older patients for fluoroquinolone therapy.

Key Words: drug resistance • Mycobacterium tuberculosis • fluoroquinolones • surgery

This article has been cited by other articles:

				E. S. Guy and A. Mallampalli Review: Managing TB in the 21st century: existing and novel drug therapies Therapeutic Advances in Respiratory Disease, December 1, 2008; 2(6): 401 - 408. [Abstract] [PDF]

				Y. Shiraishi, N. Katsuragi, H. Kita, M. Toishi, and T. Onda Experience with pulmonary resection for extensively drug-resistant tuberculosis Interactive CardioVascular and Thoracic Surgery, December 1, 2008; 7(6): 1075 - 1078. [Abstract] [Full Text] [PDF]

				D. H. Kim, H. J. Kim, S.-K. Park, S.-J. Kong, Y. S. Kim, T.-H. Kim, E. K. Kim, K. M. Lee, S. S. Lee, J. S. Park, et al. Treatment Outcomes and Long-term Survival in Patients with Extensively Drug-resistant Tuberculosis Am. J. Respir. Crit. Care Med., November 15, 2008; 178(10): 1075 - 1082. [Abstract] [Full Text] [PDF]

				E. D. Chan, M. J. Strand, and M. D. Iseman Treatment Outcomes in Extensively Resistant Tuberculosis N. Engl. J. Med., August 7, 2008; 359(6): 657 - 659. [Full Text] [PDF]

				G. B. Migliori, C. Lange, E. Girardi, R. Centis, G. Besozzi, K. Kliiman, L. R. Codecasa, A. Spanevello, D. M. Cirillo, and the SMIRA/TBNET Study Group Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur. Respir. J., April 1, 2008; 31(4): 904 - 905. [Full Text] [PDF]

				D. Almeida, E. Nuermberger, S. Tyagi, W. R. Bishai, and J. Grosset In Vivo Validation of the Mutant Selection Window Hypothesis with Moxifloxacin in a Murine Model of Tuberculosis Antimicrob. Agents Chemother., December 1, 2007; 51(12): 4261 - 4266. [Abstract] [Full Text] [PDF]

				S. Matrat, N. Veziris, C. Mayer, V. Jarlier, C. Truffot-Pernot, J. Camuset, E. Bouvet, E. Cambau, and A. Aubry Functional Analysis of DNA Gyrase Mutant Enzymes Carrying Mutations at Position 88 in the A Subunit Found in Clinical Strains of Mycobacterium tuberculosis Resistant to Fluoroquinolones Antimicrob. Agents Chemother., December 1, 2006; 50(12): 4170 - 4173. [Abstract] [Full Text] [PDF]

				C-Y. Chiang, D. A. Enarson, M-C. Yu, K-J. Bai, R-M. Huang, C-J. Hsu, J. Suo, and T-P. Lin Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study Eur. Respir. J., November 1, 2006; 28(5): 980 - 985. [Abstract] [Full Text] [PDF]

				D. E. Griffith, B. A. Brown-Elliott, B. Langsjoen, Y. Zhang, X. Pan, W. Girard, K. Nelson, J. Caccitolo, J. Alvarez, S. Shepherd, et al. Clinical and Molecular Analysis of Macrolide Resistance in Mycobacterium avium Complex Lung Disease Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 928 - 934. [Abstract] [Full Text] [PDF]

				H. J. Kim, C. H. Kang, Y. T. Kim, S-W. Sung, J. H. Kim, S. M. Lee, C-G. Yoo, C-T. Lee, Y. W. Kim, S. K. Han, et al. Prognostic factors for surgical resection in patients with multidrug-resistant tuberculosis Eur. Respir. J., September 1, 2006; 28(3): 576 - 580. [Abstract] [Full Text] [PDF]

				T. H. Holtz, M. Sternberg, S. Kammerer, K. F. Laserson, V. Riekstina, E. Zarovska, V. Skripconoka, C. D. Wells, and V. Leimane Time to Sputum Culture Conversion in Multidrug-Resistant Tuberculosis: Predictors and Relationship to Treatment Outcome Ann Intern Med, May 2, 2006; 144(9): 650 - 659. [Abstract] [Full Text] [PDF]

				M. Scharitzer, G. Dekan, L. Stiebellehner, and A. A. Bankier An 83-year-old female with worsening dyspnoea and bleeding from a cavernostomy Eur. Respir. J., January 1, 2006; 27(1): 233 - 237. [Full Text] [PDF]

				P. Nahid, M. Pai, and P. C. Hopewell Advances in the diagnosis and treatment of tuberculosis. Proceedings of the ATS, January 1, 2006; 3(1): 103 - 110. [Abstract] [Full Text] [PDF]

				F. Giannoni, E. Iona, F. Sementilli, L. Brunori, M. Pardini, G. B. Migliori, G. Orefici, and L. Fattorini Evaluation of a New Line Probe Assay for Rapid Identification of gyrA Mutations in Mycobacterium tuberculosis Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2928 - 2933. [Abstract] [Full Text] [PDF]

				L. P. Ormerod Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment Br. Med. Bull., June 14, 2005; 73-74(1): 17 - 24. [Abstract] [Full Text] [PDF]

				R. M. Granich, P. Oh, B. Lewis, T. C. Porco, and J. Flood Multidrug Resistance Among Persons With Tuberculosis in California, 1994-2003 JAMA, June 8, 2005; 293(22): 2732 - 2739. [Abstract] [Full Text] [PDF]

				B. Nemery, W. W. Yew, R. Albert, C. Brun-Buisson, W. MacNee, F. J. Martinez, D. C. Angus, and E. Abraham Tuberculosis, Nontuberculous Lung Infection, Pleural Disorders, Pulmonary Function, Respiratory Muscles, Occupational Lung Disease, Pulmonary Infections, and Social Issues in AJRCCM in 2004 Am. J. Respir. Crit. Care Med., March 15, 2005; 171(6): 554 - 562. [Full Text] [PDF]

				P. R. Mohapatra Fluoroquinolones in Multidrug-Resistant Tuberculosis Am. J. Respir. Crit. Care Med., October 15, 2004; 170(8): 920 - 921. [Full Text]

				Y. Shiraishi, Y. Nakajima, N. Katsuragi, M. Kurai, and N. Takahashi Resectional surgery combined with chemotherapy remains the treatment of choice for multidrug-resistant tuberculosis J. Thorac. Cardiovasc. Surg., October 1, 2004; 128(4): 523 - 528. [Abstract] [Full Text] [PDF]

				D. E. Griffith Treatment of Multidrug-resistant Tuberculosis: Should You Try This at Home? Am. J. Respir. Crit. Care Med., May 15, 2004; 169(10): 1082 - 1083. [Full Text] [PDF]